Shidlovski/iStock via Getty Images Thesis overview RAPT Therapeutics (NASDAQ:RAPT) is developing oral small molecule therapies for inflammation (atopic dermatitis and asthma) and oncology indications. The most advanced candidate is zelnecirnon (ZEL) currently in ph2 stage for the indications of atopic dermatitis (AD) and asthma, with promising phase 1 safety and efficacy results in AD. RAPT…
JHVEPhoto Since I presented my ‘Strong Buy’ thesis for Veeva Systems (NYSE:VEEV) in June 2023, their stock price has surged by 21%. I discussed their data analytics and AI capabilities in the healthcare industry. They guide 15.5% revenue growth and 27% adjusted operating income growth for FY25. Veeva clinical platform connects clinical operations and data…
FatCamera/E+ via Getty Images Amid the volatile terrain that is biopharmaceuticals, Day One Biopharmaceuticals (NASDAQ:DAWN) is a leader when it comes to pediatric oncology. Day One, through its lead candidate, tovorafenib, has positioned itself as a player committed to addressing the unmet needs of pediatric cancer patients, and it has been progressing through clinical trials…
apomares/E+ via Getty Images Introduction & Thesis Shares of biopharma Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) are ~60% off their May highs, despite holding an FDA-approved key drug (Inpefa) for heart failure in its portfolio. The sell-off is largely attributed to investor concerns over Inpefa’s market uptake amid a perfect storm of competition from pharma heavyweights like…
kaetana_istock/iStock via Getty Images At a Glance In my previous analysis, I recommended a “Sell” position on Cytokinetics (NASDAQ:CYTK), a sentiment I largely maintain. The company faces heightened scrutiny with a declining revenue base, which fell from $89M to a meager $0.9M in Q2 2023. Aggressive R&D spending of $83.2M, largely funneled into cardiac myosin…
Pgiam/iStock via Getty Images Investment updates Since the last publication, shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) have failed to catch a bid and pushed further to the downside. I rated RARE a speculative buy in February, and after a short snapback rally, it sold off quickly following its Q2 numbers and amid the broad selloff…
DarkGel/iStock via Getty Images Lyell (NASDAQ:LYEL) is a developer of T-cell therapies for patients with solid tumors. It is in early clinical stage, and has two wholly owned programs targeting a variety of solid tumors. These are personalized, functional and longer duration T cell therapies that are highly reactive to both hot and cold tumors….
AWS HealthScribe is designed to generate clinical notes for two medical specialists- general medicine and orthopedics. AWS (Amazon Web Service) has rolled out HealthScribe, a new service for healthcare software providers powered by Amazon Bedrock. The IT service management company announced the AI tool on July 26th at the AWS Summit New York. According to the announcement,…